Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BMS Reacquisition Bulks Up ASLAN’s Deal Chest

Executive Summary

Singapore's ASLAN has licensed back to originator BMS the Asian rights to a novel oncology molecule with potential as both a mono and combination therapy, boosting funding for potential future deals in the process.

You may also be interested in...

ASLAN Firms Up IPO Plans As Lead Asset Progresses

Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.

ASLAN Refills Pipeline With Homegrown Immuno-Onc Asset

Singapore's ASLAN has signed its second deal in the past few weeks, acquiring global rights to an early stage immuno-oncology molecule that helps to fill a pipeline hole left by a recent out-licensing deal with Bristol-Myers Squibb.

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts